Book
diabetic retinopathy and maculopathy management
- REFERENCES
1. Nanditha A, Ma RC, Ramachandran A, Snehalatha C, Chan JC, Chia KS, et al. Diabetes in Asia and the Pacific: Implications for the global epidemic. Diabetes Care 2016;39:472‑485.
2. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4‑14.
3. Prevention of blindness from diabetes mellitus: report of a WHO consultation in Geneva,
Switzerland, 9-11 November 2005. Available from: http://www.who.int/blindness/Prevention%20 of%20Blindness%20from%20Diabetes%20Mellitus‑with‑coversmall.pdf. [Last accessed on 2015 Dec 27].
4. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 2014;103:137‑49.
5. International Diabetes Federation. IDF Diabetes Atlas. 6th ed., 2015. Available from: http://www.diabetesatlas.org/component/ attachments/?task=download & id=116. [Last accessed on 2016 Jan 25].
6. Katibeh M, Pakravan M, Yaseri M, Pakbin M, Soleimanizad R. Prevalence and causes of visual impairment and blindness in central Iran; The Yazd Eye Study. J Ophthalmic Vis Res 2015;10:279‑285.
7. Dehghan MH, Katibeh M, Ahmadieh H, Nourinia R, Yaseri M. Prevalence and risk factors for diabetic retinopathy in the 40 to 80 year-old population in Yazd, Iran: The Yazd Eye Study. J Diabetes 2015;7:139‑141.
8. Judah G, Vlaev I, Gunn L, King D, King D, Valabhji J, et al. Incentives in Diabetic Eye Assessment by Screening (IDEAS): Study protocol of a three-arm randomized controlled trial using financial incentives to increase screening uptake in London. BMC Ophthalmol 2016;16:28.
9. Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol 2007;14:179‑183.
10. Resnikoff S, Pascolini D, Etya’ale D, Kocur I, Pararajasegaram R, Pokharel GP, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004;82:844‑851.
11. Moss SE, Klein R, Klein BE. The 14‑year incidence of visual loss in a diabetic population.
Ophthalmology 1998;105:998‑1003.
12. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 2010;376:124‑136.
13. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984;102:527‑532.
14. Hatef E, Fotouhi A, Hashemi H, Mohammad K, Jalali KH. Prevalence of retinal diseases and their pattern in Tehran: The Tehran eye study. Retina 2008;28:755‑762.
15. Gilbert C, Gordon I, Mukherjee CR, Govindhari V. Guidelines for the prevention and management of diabetic retinopathy and diabetic eye disease in India: A synopsis. Indian J Ophthalmol 2020;68:S63-6.
16. Indian Institute of Public Health, Hyderabad, 2019. Guidelines for the Prevention and Management of Diabetic Retinopathy and Diabetic Eye Disease in India. Hyderabad, India: Indian Institute of Public Health.
17. Rajavi Z, Safi S, Javadi MA, Azarmina M, Moradian S, Entezari M, et al. Diabetic retinopathy clinical practice guidelines: Customized for Iranian population. J Ophthalmic Vis Res 2016;11:394-414.
18. Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakonda A,Ying G, Diabetic retinopathy preferred practice pattern, DOI:https://doi.org/10.1016/j.ophtha.2019.09.025
Royal college of ophthalmologists, Diabetic retinopathy guidelines.
19. Ferris F. Early photocoagulation in patients with either type I or type II diabetes. Trans Am Ophthalmol Soc. 1996;94: 505-37.
20. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. . Ophthalmology. 1991;98(5 Suppl): 766-85.
21. Early Treatment Diabetic Retinopathy Study research Group. Photocoagulation for diabetic macular edema. Study report number 1. Arch Ophthalmol. 1985;103(12): 1796-806.
22. Lövestam‑Adrian M, Agardh CD, Torffvit O, Agardh E. Type 1 diabetes patients with severe non‑proliferative retinopathy may benefit from panretinal photocoagulation. Acta Ophthalmol Scand 2003;81:221‑225.
23. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1987;94:761‑774.
24. Diabetic Retinopathy Study Research Group. Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report number 14. Int Ophthalmol Clin 1987;27:239‑253.
25. Zaluski S, Marcil G, Lamer L, Lambert J. Study of the visual field using automated static perimetry following panretinal photocoagulation in the diabetic. J Fr Ophtalmol 1986;9:395‑401.
26. Buckley SA, Jenkins L, Benjamin L. Fields, DVLC and panretinal photocoagulation. Eye (Lond) 1992;6(Pt 6):623‑625.
27. Pahor D. Visual field loss after argon laser panretinal photocoagulation in diabetic retinopathy: Full‑versus mild‑scatter coagulation. Int Ophthalmol 1998;22:313‑319.
28. Diabetic Retinopathy Clinical Research Network (DRCR.net), Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, et al. Three-year follow-up of a randomized trial comparing focal/ grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009;127:245‑251.
29. Gillies MC, Simpson JM, Gaston C, Hunt G, Ali H, Zhu M, et al. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology 2009;116:2182‑2187.
30. Lam DS, Chan CK, Mohamed S, Lai TY, Lee VY, Liu DT, et al. Intravitreal triamcinolone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema: Six‑month outcomes. Ophthalmology 2007;114:2162‑2167.
31. Gillies MC, McAllister IL, Zhu M, Wong W, Louis D, Arnold JJ, et al. Pretreatment with intravitreal triamcinolone before laser for diabetic macular edema: 6-month results of a randomized, placebo‑controlled trial. Invest Ophthalmol Vis Sci 2010;51:2322‑2328.
32. Diabetic Retinopathy Clinical Research Network, Chew E, Strauber S, Beck R, Aiello LP, Antoszyk A, et al. Randomized trial of peribulbar triamcinolone acetonide with and without focal photocoagulation for mild diabetic macular edema: A pilot study. Ophthalmology 2007;114:1190‑1196.
33. Gillies MC, Simpson JM, Billson FA, Luo W, Penfold P, Chua W, et al. Safety of an intravitreal injection of triamcinolone: Results from a randomized clinical trial. Arch Ophthalmol 2004;122:336‑340.
34. Quiram PA, Gonzales CR, Schwartz SD. Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 2006;141:580‑582.
35. Haller JA, Kuppermann BD, Blumenkranz MS, Williams GA, Weinberg DV, Chou C, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010;128:289‑296.
36. Campochiaro PA, Hafiz G, Shah SM, Bloom S, Brown DM, Busquets M, et al. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology
2010;117:1393‑1399.e3.
37. Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012;119:2125‑2132.
38. Adamis AP, Miller JW, Bernal MT, D’Amico DJ, Folkman J, Yeo TK, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994 15;118:445‑450.
39. Cunningham ET Jr., Adamis AP, Altaweel M, Aiello LP, Bressler NM, D’Amico DJ, et al. A phase II randomized double‑masked trial of pegaptanib, an anti‑vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005;112:1747‑1757.
40. Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D, et al. Primary end point (Six Months) results of the ranibizumab for edema of the mAcula in diabetes (READ‑2) study. Ophthalmology 2009;116:2175‑2181.e1.
41. Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatef E, Do DV, et al. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ‑2) study. Ophthalmology 2010;117:2146‑2151.
42. Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): A 12-month, randomized, controlled, double‑masked, multicenter phase II study. Diabetes Care 2010;33:2399‑2405.
43. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al. The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011;118:615‑625.
44. Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064‑1077.e35.
45. Goyal S, Lavalley M, Subramanian ML. Meta‑analysis and review on the effect of bevacizumab in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2011;249:15‑27.
46. Yilmaz T, Cordero-Coma M, Gallagher MJ, Teasley LA. Systematic review of intravitreal bevacizumab injection for treatment of primary diabetic macular oedema. Acta Ophthalmol 2011;89:709‑717.
47. Michaelides M, Kaines A, Hamilton RD, Fraser‑Bell S, Rajendram R, Quhill F, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12‑month data: Report 2. Ophthalmology 2010;117:1078‑1086.e2.
48. Arevalo JF, Sanchez JG, Wu L, Maia M, Alezzandrini AA, Brito M, et al. Primary intravitreal bevacizumab for diffuse diabetic macular edema: The Pan‑American Collaborative Retina Study Group at 24 months. Ophthalmology 2009;116:1488‑1497, 1497.e1.
49. Lam DS, Lai TY, Lee VY, Chan CK, Liu DT, Mohamed S, et al. Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: Six-month results of a randomized controlled trial. Retina 2009;29:292‑299.
50. Ahmadieh H, Ramezani A, Shoeibi N, Bijanzadeh B, Tabatabaei A, Azarmina M, et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 2008;246:483‑489.
51. Soheilian M, Ramezani A, Obudi A, Bijanzadeh B, Salehipour M, Yaseri M, et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 2009;116:1142‑1150.
52. Solaiman KA, Diab MM, Abo-Elenin M. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema. Retina 2010;30:1638‑1645.
53. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol 2008;92:667‑668.
54. Do DV, Nguyen QD, Shah SM, Browning DJ, Haller JA, Chu K, et al. An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap‑Eye in patients with diabetic macular oedema. Br J Ophthalmol 2009;93:144‑149.
55. Do DV, Nguyen QD, Boyer D, Schmidt-Erfurth U, Brown DM, Vitti R, et al. One‑year outcomes of the da Vinci Study of VEGF Trap‑Eye in eyes with diabetic macular edema. Ophthalmology 2012;119:1658‑1665.
56. Lanzagorta-Aresti A, Palacios-Pozo E, Menezo Rozalen JL, Navea‑Tejerina A. Prevention of vision loss after cataract surgery in diabetic macular edema with intravitreal bevacizumab: A pilot study. Retina 2009;29:530‑555.
57. Akinci A, Muftuoglu O, Altinsoy A, Ozkilic E. Phacoemulsification with intravitreal bevacizumab and triamcinolone acetonide injection in diabetic patients with clinically significant macular edema and cataract. Retina 2011;31:755‑758.
58. Fard MA, Yazdanei Abyane A, Malihi M. Prophylactic intravitreal bevacizumab for diabetic macular edema (thickening) after cataract surgery: Prospective randomized study. Eur J Ophthalmol 2011;21:276‑281.
59. Ishibashi T, Miki K, Sorgente N, Patterson R, Ryan SJ. Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. Arch Ophthalmol 1985;103:708‑711.
60. Danis RP, Bingaman DP, Yang Y, Ladd B. Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology 1996;103:2099‑2104.
61. Ciulla TA, Criswell MH, Danis RP, Hill TE. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser‑treated rat model. Arch Ophthalmol 2001;119:399‑404.
62. Wang YS, Friedrichs U, Eichler W, Hoffmann S, Wiedemann P. Inhibitory effects of triamcinolone acetonide on bFGF‑induced migration and tube formation in choroidal microvascular endothelial cells. Graefes Arch Clin Exp Ophthalmol 2002;240:42‑48.
63. Jonas JB, Hayler JK, Söfker A, Panda‑Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2001;131:468‑471.
64. Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 1998;341:309‑315.
65. Brooks HL Jr., Caballero S Jr., Newell CK, Steinmetz RL, Watson D, Segal MS, et al. Vitreous levels of vascular endothelial growth factor and stromal‑derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. Arch Ophthalmol 2004;122:1801‑1817.
66. Jonas JB, Kreissig I, Söfker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2003;121:57‑61.
67. Jonas JB, Söfker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 2001;132:425‑427.
68. Jonas JB. Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases. Acta Ophthalmol Scand 2005;83:645‑663.
69. Jonas JB, Degenring RF, Kamppeter BA. Outcome of eyes undergoing trabeculectomy after intravitreal injections of triamcinolone acetonide. J Glaucoma 2004;13:261.
70. Kuhn F, Barker D. Intravitreal injection of triamcinolone acetonide for diabetic macular edema. Arch Ophthalmol 2004;122:1082‑1083.
71. Savage H, Roh M. Safety and efficacy of intravitreal triamcinolone. Arch Ophthalmol 2004;122:1083.
72. Patelli F, Fasolino G, Radice P, Russo S, Zumbo G, DI Tizio FM, et al. Time course of changes in retinal thickness and visual acuity after intravitreal triamcinolone acetonide for diffuse diabetic macular edema with and without previous macular laser treatment. Retina 2005;25:840‑845.
73. Larsson J, Zhu M, Sutter F, Gillies MC. Relation between reduction of foveal thickness and visual acuity in diabetic macular edema treated with intravitreal triamcinolone. Am J Ophthalmol 2005;139:802‑806.
74. Massin P, Audren F, Haouchine B, Erginay A, Bergmann JF, Benosman R, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: Preliminary results of a prospective controlled trial. Ophthalmology 2004;111:218‑224.
75. Avitabile T, Longo A, Reibaldi A. Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am J Ophthalmol 2005;140:695‑702.
76. Sutter FK, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: Three‑month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology 2004;111:2044‑2049.
77. Audren F, Lecleire‑Collet A, Erginay A, Haouchine B, Benosman R, Bergmann JF, et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: Phase 2 trial comparing 4 mg vs 2 mg. Am J Ophthalmol 2006;142:794‑799.
78. Jonas JB, Kamppeter BA, Harder B, Vossmerbaeumer U, Sauder G, Spandau UH. Intravitreal triamcinolone acetonide for diabetic macular edema: A prospective, randomized study. J Ocul Pharmacol Ther 2006;22:200‑207.
79. Audren F, Erginay A, Haouchine B, Benosman R, Conrath J, Bergmann JF, et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6‑month results of a prospective controlled trial. Acta Ophthalmol Scand 2006;84:624‑630.
80. Lam DS, Chan CK, Mohamed S, Lai TY, Li KK, Li PS, et al. A prospective randomised trial of different doses of intravitreal triamcinolone for diabetic macular oedema. Br J Ophthalmol 2007;91:199‑203.
81. Kang SW, Sa HS, Cho HY, Kim JI. Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema. Arch Ophthalmol 2006;124:653‑658.
82. Parke DW. Intravitreal triamcinolone and endophthalmitis. Am J Ophthalmol 2003;136:918‑919.
83. Roth DB, Chieh J, Spirn MJ, Green SN, Yarian DL, Chaudhry NA. Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 2003;121:1279‑1282.
84. Jonas JB, Kreissig I, Spandau UH, Harder B. Infectious and noninfectious endophthalmitis after intravitreal high‑dosage triamcinolone acetonide. Am J Ophthalmol 2006;141:579‑580.
85. Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005;112:593‑598.
86. Konstantopoulos A, Williams CP, Newsom RS, Luff AJ. Ocular morbidity associated with intravitreal triamcinolone acetonide. Eye (Lond) 2007;21:317‑320.
87. Lang Y, Leibu R, Shoham N, Miller B, Perlman I. Evaluation of intravitreal kenalog toxicity in humans. Ophthalmology 2007;114:724‑731.
88. Bandello F, Polito A, Pognuz DR, Monaco P, Dimastrogiovanni A, Paissios J. Triamcinolone as adjunctive treatment to laser panretinal photocoagulation for proliferative diabetic retinopathy. Arch Ophthalmol 2006;124:643‑650.
89. Spandau UH, Derse M, Schmitz-Valckenberg P, Papoulis C, Jonas JB. Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema. Br J Ophthalmol 2005;89:999‑1003.
90. Jonas JB, Degenring RF, Kamppeter BA, Kreissig I, Akkoyun I. Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema. Am J Ophthalmol 2004;138:158‑160.
91. Rodriguez-Coleman H, Yuan P, Kim H, Gravlin L, Srivastava S, Csaky KG, et al. Intravitreal injection of triamcinolone for diffuse macular edema. Arch Ophthalmol 2004;122:1085‑1116.
92. Negi AK, Vernon SA, Lim CS, Owen‑Armstrong K. Intravitreal triamcinolone improves vision in eyes with chronic diabetic macular oedema refractory to laser photocoagulation. Eye (Lond) 2005;19:747‑751.
93. Gibran SK, Cullinane A, Jungkim S, Cleary PE. Intravitreal triamcinolone for diffuse diabetic macular oedema. Eye 2006;20:720‑724.
94. Jonas JB, Spandau UH, Kamppeter BA, Vossmerbaeumer U, Harder B, Sauder G. Repeated intravitreal high‑dosage injections of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology 2006;113:800‑804.
95. Kim H, Csaky KG, Gravlin L, Yuan P, Lutz RJ, Bungay PM, et al. Safety and pharmacokinetics of a preservative‑free triamcinolone acetonide formulation for intravitreal administration. Retina 2006;26:523‑530.
96. Pearson P, Levy B, Comstock T, Fluocinolone Acetonide Implant Study Group. Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: 3‑year results of a multi‑centre clinical trial. Invest Ophthalmol Vis Sci 2006;47 5442 [E‑abstract 5442].
97. Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007;125:309‑317.
98. Verma LK, Vivek MB, Kumar A, Tewari HK, Venkatesh P. A prospective controlled trial to evaluate the adjunctive role of posterior subtenon triamcinolone in the treatment of diffuse diabetic macular edema. J Ocul Pharmacol Ther 2004;20:277‑284.
99. Bakri SJ, Kaiser PK. Posterior subtenon triamcinolone acetonide for refractory diabetic macular edema. Am J Ophthalmol 2005;139:290‑294.
100. Cardillo JA, Melo LA Jr., Costa RA, Skaf M, Belfort R Jr., Souza-Filho AA, et al. Comparison of intravitreal versus posterior sub‑Tenon’s capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology 2005;112:1557‑1563.
101. Bonini‑Filho MA, Jorge R, Barbosa JC, Calucci D, Cardillo JA, Costa RA. Intravitreal injection versus sub‑Tenon’s infusion of triamcinolone acetonide for refractory diabetic macular edema: A randomized clinical trial. Invest Ophthalmol Vis Sci 2005;46:3845‑3849.
102. Caldwell RB, Bartoli M, Behzadian MA, El-Remessy AE, Al‑Shabrawey M, Platt DH, et al. Vascular endothelial growth factor and diabetic retinopathy: Role of oxidative stress. Curr Drug Targets 2005;6:511‑524.
103. Zhang SX, Ma JX. Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy. Prog Retin Eye Res 2007;26:1‑37.
104. Ng EW, Shima DT, Calias P, Cunningham ET Jr., Guyer DR, Adamis AP. Pegaptanib, a targeted anti‑VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006;5:123‑132.
105. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age‑related macular degeneration. N Engl J Med 2004;351:2805‑2816.
106. Adamis AP, Altaweel M, Bressler NM, Cunningham ET Jr., Davis MD, Goldbaum M, et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2006;113:23‑28.
107. Churchill AJ, Carter JG, Lovell HC, Ramsden C, Turner SJ, Yeung A, et al. VEGF polymorphisms are associated with neovascular age‑related macular degeneration. Hum Mol Genet 2006 1;15:2955‑2961.
108. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432‑1444.
109. Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 2006;113:1706‑1712.
110. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006;26:275‑278.
111. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695.e1‑15.
112. Mason JO 3rd, Nixon PA, White MF. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2006;142:685‑688.
113. Oshima Y, Sakaguchi H, Gomi F, Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2006;142:155‑158.
114. Grisanti S, Biester S, Peters S, Tatar O, Ziemssen F, Bartz-Schmidt KU; Tuebingen Bevacizumab Study Group. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol 2006;142:158‑160.
115. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006;26:352‑354.
116. Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006;26:999‑1005.
117. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JG, Wu L, Maia M, et al. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: Results from the Pan‑American Collaborative Retina Study Group at 6‑month follow‑up. Ophthalmology 2007;114:743‑750.
118. Yanyali A, Aytug B, Horozoglu F, Nohutcu AF. Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am J Ophthalmol 2007;144:124‑126.
119. Isaacs TW, Barry C. Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intravitreal injection of bevacizumab (Avastin). Clin Experiment Ophthalmol 2006;34:802‑803.
120. Bakri SJ, Donaldson MJ, Link TP. Rapid regression of disc neovascularization in a patient with proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab. Eye (Lond) 2006;20:1474‑1475.
121. Diabetic Retinopathy Clinical Research Network, Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007;114:1860‑1867.
122. Zhao LQ, Zhu H, Zhao PQ, Hu YQ. A systematic review and meta‑analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy. Br J Ophthalmol 2011;95:1216‑1222.
123. Ahmadieh H, Shoeibi N, Entezari M, Monshizadeh R. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: A randomized clinical trial. Ophthalmology 2009;116:1943‑1948.
124. Rizzo S, Genovesi-Ebert F, Di Bartolo E, Vento A, Miniaci S, Williams G. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol 2008;246:837‑842.
125. Yeoh J, Williams C, Allen P, Buttery R, Chiu D, Clark B, et al. Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: A prospective case series. Clin Experiment Ophthalmol 2008;36:449‑454.
126. Oshima Y, Shima C, Wakabayashi T, Kusaka S, Shiraga F, Ohji M, et al. Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment. Ophthalmology 2009;116:927‑938.
127. Zhang ZH, Liu HY, Hernandez-Da Mota SE, Romano MR, Falavarjani KG, Ahmadieh H, et al. Vitrectomy with or without preoperative intravitreal bevacizumab for proliferative diabetic retinopathy: A meta-analysis of randomized controlled trials. Am J Ophthalmol 2013;156:106‑115.e2.
